Federal regulators have informed Pfizer and BioNTech that they plan to approve the companies’ request to store their vaccine at standard freezer temperatures instead of in ultra-cold conditions, potentially expanding the number of sites that could administer shots, according to two people familiar with the companies who spoke on condition of anonymity.